G protein-coupled receptors and obesity
G protein-coupled receptors (GPCRs) have emerged as important drug targets for various chronic diseases, including obesity and diabetes. Obesity is a complex chronic disease that requires long term management predisposing to type 2 diabetes, heart disease, and some cancers. The therapeutic landscape...
Main Author: | Alessandro Pocai |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1301017/full |
Similar Items
-
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
by: Isabella Zaffina, et al.
Published: (2023-02-01) -
Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01) -
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01) -
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01) -
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)